|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.5850 - 1.6200|
|52 Week Range||0.6000 - 4.4900|
|Beta (5Y Monthly)||0.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide Life Sciences and other industries, today announced the award of a key U.S. patent entitled "Sample Preparation Devices and Methods". This new patent (US 10,710,082) brings the Company's Intellectual Property ("IP") estate up to a total of 25 issued patents.
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2020 financial results and to provide a business update, including discussions on progress made in the development of the Company's proprietary Ultra Shear Technology™ ("UST™) Platform and in the pending merger of PBI, Cannaworx, and SkinScience Labs.
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, and food & beverage industries, today announced that the Company has entered into a worldwide co-marketing agreement with German-based Leica Microsystems CMS GmbH, a Danaher company. This historic alliance is expected to offer transformative new empowerment to cancer research worldwide, by integrating the latest enabling technologies in capturing, isolating, and preparing precious biopsy samples for superior analysis of relevant biomarkers of disease state and treatment response.